

ELSEVIER

Diabetes Research and Clinical Practice 62 (2003) 213–215

DIABETES RESEARCH
AND
CLINICAL PRACTICE


www.elsevier.com/locate/diabres


Author index of volume 62

- Alaniz, C., see Ilag, L.L. 62, 23
Altuntaş, Y., see Sargin, H. 62, 79
Andersen, P.K., see Kessing, L.V. 62, 113
Antonucci, G., see Lepore, C. 62, 61
Azuma, J., see Iwata, E. 62, 55
- Babatunde, S., see Nyenwe, E.A. 62, 177
Bajotto, G., see Qin, B. 62, 139
Bardini, G., see Seghieri, G. 62, 203
Beattie, S.D., see Malone, J.K. 62, 187
Bennett, P.H., see Vozarova de Courten, B. 62, 95
Benzi, L., see Di Cianni, G. 62, 131
Bhonde, R.R., see Risbud, M.V. 62, 211
Bottone, P., see Di Cianni, G. 62, 131
- Campaigne, B.N., see Malone, J.K. 62, 187
Chatzianagnostou, K., see Di Cianni, G. 62, 131
Cho, Y.M., see Hong, H.K. 62, 1
Clifton, P.M., see Morris, A.M. 62, 197
Cuccuru, I., see Di Cianni, G. 62, 131
- de Courten, M., see Vozarova de Courten, B. 62, 95
Del Prato, S., see Di Cianni, G. 62, 131
Di Cianni, G., L. Volpe, C. Lencioni, R. Miccoli, I. Cuccuru, A. Ghio, K. Chatzianagnostou, P. Bottone, G. Teti, S. Del Prato, L. Benzi, Prevalence and risk factors for gestational diabetes assessed by universal screening 62, 131
- Egyenes, H.P., see Vozarova de Courten, B. 62, 95
Ernst, R.D., see Ilag, L.L. 62, 23
Eslick, G.D., see Sherry, E. 62, 65
- Fascetti, S., see Seghieri, G. 62, 203
Franconi, F., see Seghieri, G. 62, 203
Frey, J., see Malecki, M.T. 62, 105
Fujii, M., see Miyatake, N. 62, 149
Fujii, Y., see Shimizu, I. 62, 33
Fujimoto, S., see Oya, M. 62, 69
Fukuda, K., see Oya, M. 62, 69
- Galdon, G., see González-Clemente, J.M. 62, 123
Ghio, A., see Di Cianni, G. 62, 131
Giménez-Pérez, G., see González-Clemente, J.M. 62, 123
González-Clemente, J.M., G. Galdon, J. Mitjavila, A. Miñarro, G. Giménez-Pérez, D. Mauricio, Translation of the recommendations for the diagnosis of diabetes mellitus into daily clinical practice in a primary health care setting 62, 123
Grondin, L., see Ilag, L.L. 62, 23
- Hanafusa, T., see Shimizu, I. 62, 33
Hanson, R.L., see Vozarova de Courten, B. 62, 95
Hayashi, T., see Takahashi-Yasuno, A. 62, 169
Heilbronn, L.K., see Morris, A.M. 62, 197
Herman, W.H., see Ilag, L.L. 62, 23
Hong, H.K., Y.M. Cho, K.-H. Park, C.-T. Lee, H.K. Lee, K.S. Park, Peroxisome proliferator-activated receptor gamma mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells 62, 1
Hosoda, K., see Takahashi-Yasuno, A. 62, 169
Hosokawa, M., see Oya, M. 62, 69
Howard, A.S., see Malone, J.K. 62, 187
- Iacobellis, G., see Lepore, C. 62, 61
Igarashi, T., see Iwata, E. 62, 55
Ihekweba, A.E., see Nyenwe, E.A. 62, 177
Iizuka, K.-I., see Koizumi, M. 62, 17
Ilag, L.L., S. Kronick, R.D. Ernst, L. Grondin, C. Alaniz, L. Liu, W.H. Herman, Impact of a critical pathway on inpatient management of diabetic ketoacidosis 62, 23
Imagawa, A., see Shimizu, I. 62, 33
Inoue, G., see Takahashi-Yasuno, A. 62, 169
Ishida, T., see Ohsawa, I. 62, 9
Iwata, E., I. Yamamoto, T. Motomura, S. Tsubakimori, S. Nohnen, M. Ohmoto, T. Igarashi, J. Azuma, The association of *Pro12Ala* polymorphism in *PPARγ2* with lower carotid artery IMT in Japanese 62, 55
- Johnson, P.A., see Malone, J.K. 62, 187
- Kammerer, L., see Lengyel, Z. 62, 159
Kawasaki, E., see Shimizu, I. 62, 33
Kessing, L.V., F.M. Nilsson, V. Siersma, P.K. Andersen, No increased risk of developing depression in diabetes compared to other chronic illness 62, 113
Kind, K.L., see Morris, A.M. 62, 197
Kira, S., see Miyatake, N. 62, 149
Klupa, T., see Malecki, M.T. 62, 105
Kobayashi, J., T. Maruyama, H. Watanabe, A. Kudoh, S. Tateishi, T. Sasaki, S. Murano, M. Watanabe, Gender differences in the effect of type 2 diabetes on serum lipids, pre-heparin plasma lipoprotein lipase mass and other

- metabolic parameters in Japanese population 62, 39
- Koizumi, M., H. Shimizu, K. Shimomura, S. Oh-I, Y. Tomita, T. Kudo, K.-I. Iizuka, M. Mori, Relationship between hyperinsulinemia and pulse wave velocity in moderately hyperglycemic patients 62, 17
- Kounoue, E., see Shimizu, I. 62, 33
- Kronick, S., see Ilag, L.L. 62, 23
- Kudo, T., see Koizumi, M. 62, 17
- Kudoh, A., see Kobayashi, J. 62, 39
- Kunitomi, M., see Miyatake, N. 62, 149
- Kusaka, H., see Maegawa, Y. 62, 47
- Lee, C.-T., see Hong, H.K. 62, 1
- Lee, H.K., see Hong, H.K. 62, 1
- Lencioni, C., see Di Cianni, G. 62, 131
- Lengyel, Z., L. Rosivall, C. Németh, L.K. Tóth, V. Nagy, M. Mihály, L. Kammerer, P. Vörös, Diurnal blood pressure pattern may predict the increase of urinary albumin excretion in normotensive normoalbuminuric type 1 diabetes mellitus patients 62, 159
- Lepore, C., G. Iacobellis, D. Merante, G. Antonucci, Inadequacy of therapeutic education: a risk factor of hypoglycaemia 62, 61
- Liu, L., see Ilag, L.L. 62, 23
- Maegawa, Y., T. Sugiyama, H. Kusaka, M. Mitao, N. Toyoda, Screening tests for gestational diabetes in Japan in the 1st and 2nd trimester of pregnancy 62, 47
- Makino, H., see Miyatake, N. 62, 149
- Makino, H., see Shimizu, I. 62, 33
- Malecki, M.T., J. Frey, T. Klupa, J. Skupien, M. Walus, W. Mlynarski, J. Sieradzki, The Pro12Ala polymorphism of PPAR γ 2 gene and susceptibility to type 2 diabetes mellitus in a Polish population 62, 105
- Malone, J.K., S.D. Beattie, B.N. Campaigne, P.A. Johnson, A.S. Howard, Z. Milicevic, Therapy after single oral agent failure: adding a second oral agent or an insulin mixture? 62, 187
- Maruyama, T., see Kobayashi, J. 62, 39
- Masuzaki, H., see Takahashi-Yasuno, A. 62, 169
- Matsuoka, N., see Takahashi-Yasuno, A. 62, 169
- Mauricio, D., see González-Clemente, J.M. 62, 123
- Merante, D., see Lepore, C. 62, 61
- Miccoli, R., see Di Cianni, G. 62, 131
- Mihály, M., see Lengyel, Z. 62, 159
- Milicevic, Z., see Malone, J.K. 62, 187
- Miñarro, A., see González-Clemente, J.M. 62, 123
- Mitao, M., see Maegawa, Y. 62, 47
- Mitjavila, J., see González-Clemente, J.M. 62, 123
- Miyatake, N., K. Takahashi, J. Wada, H. Nishikawa, A. Morishita, H. Suzuki, M. Kunitomi, H. Makino, S. Kira, M. Fujii, Daily exercise lowers blood pressure and reduces visceral adipose tissue areas in overweight Japanese men 62, 149
- Miyawaki, T., see Takahashi-Yasuno, A. 62, 169
- Mlynarski, W., see Malecki, M.T. 62, 105
- Mori, M., see Koizumi, M. 62, 17
- Morishita, A., see Miyatake, N. 62, 149
- Morris, A.M., L.K. Heilbronn, M. Noakes, K.L. Kind, P.M. Clifton, - 308 *Nco* I polymorphism of tumour necrosis factor α in overweight Caucasians 62, 197
- Moruzzo, D., see Seghieri, G. 62, 203
- Motomura, T., see Iwata, E. 62, 55
- Murano, S., see Kobayashi, J. 62, 39
- Nagasaki, M., see Qin, B. 62, 139
- Nagashima, K., see Oya, M. 62, 69
- Nagy, V., see Lengyel, Z. 62, 159
- Nakamura, H., see Oya, M. 62, 69
- Nakao, K., see Takahashi-Yasuno, A. 62, 169
- Németh, C., see Lengyel, Z. 62, 159
- Nilsson, F.M., see Kessing, L.V. 62, 113
- Nishikawa, H., see Miyatake, N. 62, 149
- Noakes, M., see Morris, A.M. 62, 197
- Nohnen, S., see Iwata, E. 62, 55
- Nyenwe, E.A., O.J. Odia, A.E. Ihekweba, A. Ojule, S. Babatunde, Type 2 diabetes in adult Nigerians: a study of its prevalence and risk factors in Port Harcourt, Nigeria 62, 177
- Odia, O.J., see Nyenwe, E.A. 62, 177
- Ogawa, Y., see Takahashi-Yasuno, A. 62, 169
- Oh-I, S., see Koizumi, M. 62, 17
- Ohmoto, M., see Iwata, E. 62, 55
- Ohsawa, I., T. Ishida, Y. Oshida, K. Yamanouchi, Y. Sato, Subjective health values of individuals with diabetes in Japan: comparison of utility values with the SF-36 scores 62, 9
- Ojule, A., see Nyenwe, E.A. 62, 177
- Orbay, E., see Sargin, H. 62, 79
- Osawa, H., see Shimizu, I. 62, 33
- Oshida, Y., see Ohsawa, I. 62, 9
- Oshida, Y., see Qin, B. 62, 139
- Oya, M., M. Hosokawa, H. Tsukada, K. Fukuda, H. Nakamura, K. Tsukiyama, K. Nagashima, S. Fujimoto, Y. Yamada, Y. Seino, Effects of an aldose reductase inhibitor on gastroenteropathy in streptozotocin-diabetic rats 62, 69
- Park, K.-H., see Hong, H.K. 62, 1
- Park, K.S., see Hong, H.K. 62, 1
- Qin, B., M. Nagasaki, M. Ren, G. Bajotto, Y. Oshida, Y. Sato, Cinnamon extract (traditional herb) potentiates in vivo insulin-regulated glucose utilization via enhancing insulin signaling in rats 62, 139
- Ramachandran, A., Monotherapy of type 2 diabetes with once-daily gliclazide modified release in primary care 62, 63
- Ren, M., see Qin, B. 62, 139
- Risbud, M.V., R.R. Bhonde, Corrigendum to "Models of pancreatic regeneration in diabetes": [Diabetes Res. Clin. Pract. 58 (2003) 155-165] 62, 211
- Rosivall, L., see Lengyel, Z. 62, 159
- Sargin, H., M. Sargin, Y. Altuntaş, A.M. Şengül, E. Orbay, S. Seber, S. Uçak, A. Yayla, Comparison of lunch and bedtime

- NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes 62, 79
- Sargin, M., see Sargin, H. 62, 79
- Sasaki, T., see Kobayashi, J. 62, 39
- Sato, Y., see Ohsawa, I. 62, 9
- Sato, Y., see Qin, B. 62, 139
- Seber, S., see Sargin, H. 62, 79
- Seghieri, G., G. Bardini, S. Fascetti, D. Moruzzo, F. Franconi, Stroke is related to lower serum thyrotropin levels in patients with diabetes mellitus 62, 203
- Seino, Y., see Oya, M. 62, 69
- Şengül, A.M., see Sargin, H. 62, 79
- Sherry, E., S. Sivananthan, P.H. Warnke, G.D. Eslick, Topical phytochemicals used to salvage the gangrenous lower limbs of type 1 diabetic patients 62, 65
- Shiba, T., Improvement of insulin resistance by a new insulin secretagogue, nateglinide—analysis based on the homeostasis model 62, 87
- Shimizu, H., see Koizumi, M. 62, 17
- Shimizu, I., H. Makino, H. Osawa, E. Kounoue, A. Imagawa, T. Hanafusa, E. Kawasaki, Y. Fujii, Association of fulminant type 1 diabetes with pregnancy 62, 33
- Shimomura, K., see Koizumi, M. 62, 17
- Sieradzki, J., see Malecki, M.T. 62, 105
- Siersma, V., see Kessing, L.V. 62, 113
- Sivananthan, S., see Sherry, E. 62, 65
- Skupien, J., see Malecki, M.T. 62, 105
- Sugiyama, T., see Maegawa, Y. 62, 47
- Suzuki, H., see Miyatake, N. 62, 149
- Takahashi, K., see Miyatake, N. 62, 149
- Takahashi-Yasuno, A., H. Masuzaki, T. Miyawaki, Y. Ogawa, N. Matsuoka, T. Hayashi, K. Hosoda, G. Inoue, Y. Yoshimasa, K. Nakao, Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men 62, 169
- Tataranni, P.A., see Vozarova de Courten, B. 62, 95
- Tateishi, S., see Kobayashi, J. 62, 39
- Teti, G., see Di Cianni, G. 62, 131
- Tomita, Y., see Koizumi, M. 62, 17
- Tóth, L.K., see Lengyel, Z. 62, 159
- Toyoda, N., see Maegawa, Y. 62, 47
- Tsubakimori, S., see Iwata, E. 62, 55
- Tsukada, H., see Oya, M. 62, 69
- Tsukiyama, K., see Oya, M. 62, 69
- Uçak, S., see Sargin, H. 62, 79
- Volpe, L., see Di Cianni, G. 62, 131
- Vörös, P., see Lengyel, Z. 62, 159
- Vozar, J., see Vozarova de Courten, B. 62, 95
- Vozarova de Courten, B., M. de Courten, R.L. Hanson, A. Zahorakova, H.P. Egyenes, P.A. Tataranni, P.H. Bennett, J. Vozar, Higher prevalence of type 2 diabetes, metabolic syndrome and cardiovascular diseases in gypsies than in non-gypsies in Slovakia 62, 95
- Wada, J., see Miyatake, N. 62, 149
- Walus, M., see Malecki, M.T. 62, 105
- Warnke, P.H., see Sherry, E. 62, 65
- Watanabe, H., see Kobayashi, J. 62, 39
- Watanabe, M., see Kobayashi, J. 62, 39
- Yamada, Y., see Oya, M. 62, 69
- Yamamoto, I., see Iwata, E. 62, 55
- Yamanouchi, K., see Ohsawa, I. 62, 9
- Yayla, A., see Sargin, H. 62, 79
- Yoshimasa, Y., see Takahashi-Yasuno, A. 62, 169
- Zahorakova, A., see Vozarova de Courten, B. 62, 95





ELSEVIER

Diabetes Research and Clinical Practice 62 (2003) 217–219

DIABETES RESEARCH
AND
CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Subject index of volume 62

- Aldose reductase inhibitor;** Diabetes mellitus; Gastroenteropathy 62, 69
- Anthropometric parameters;** Visceral adipose tissue; Computed tomography 62, 149
- Arthritis;** Diabetes; Depressive disorder; Chronic illness 62, 113
- Atherosclerosis;** *Pro12Ala PPAR γ 2* polymorphism; Type 2 diabetes; Carotid artery intima-media thickness; Japanese 62, 55
- Blood pressure;** Diabetes; Nephropathy; Diurnal variation; Microalbuminuria 62, 159
- Body mass index;** Type 2 diabetes in adult Nigerians; Plasma glucose 62, 177
- Cardiovascular disease;** Ethnicity; Roma; Obesity; Type 2 diabetes 62, 95
- Carotid artery intima-media thickness;** *Pro12Ala PPAR γ 2* polymorphism; Type 2 diabetes; Atherosclerosis; Japanese 62, 55
- Chronic illness;** Diabetes; Arthritis; Depressive disorder 62, 113
- Cinnamon extract;** Euglycemic clamp; Insulin action; Insulin signaling 62, 139
- Clinical guidelines;** Diabetic ketoacidosis; Critical pathways 62, 23
- Computed tomography;** Visceral adipose tissue; Anthropometric parameters 62, 149
- Critical pathways;** Diabetic ketoacidosis; Clinical guidelines 62, 23
- Depressive disorder;** Diabetes; Arthritis; Chronic illness 62, 113
- Diabetes;** Arthritis; Depressive disorder; Chronic illness 62, 113
- Diabetes;** Nephropathy; Blood pressure; Diurnal variation; Microalbuminuria 62, 159
- Diabetes;** Utility; Preference; Quality of life; SF-36 62, 9
- Diabetes diagnosis;** Oral glucose tolerance test; Impaired fasting glucose; Impaired glucose tolerance; Primary care 62, 123
- Diabetes mellitus;** Aldose reductase inhibitor; Gastroenteropathy 62, 69
- Diabetes mellitus;** Lipoprotein lipase mass; Intra-abdominal fat; Remnant-like particle; Leptin 62, 39
- Diabetes mellitus;** Stroke; Thyrotropin 62, 203
- Diabetic ketoacidosis;** Critical pathways; Clinical guidelines 62, 23
- Diurnal variation;** Diabetes; Nephropathy; Blood pressure; Microalbuminuria 62, 159
- Endothelial cell;** Plasminogen activator inhibitor type 1; Peroxisome proliferator-activated receptor gamma; Troglitazone 62, 1
- Ethnicity;** Roma; Obesity; Cardiovascular disease; Type 2 diabetes 62, 95
- Euglycemic clamp;** Cinnamon extract; Insulin action; Insulin signaling 62, 139
- Fulminant type 1 diabetes;** Pregnancy; Viral infection; HLA; GADab 62, 33
- GADab;** Fulminant type 1 diabetes; Pregnancy; Viral infection; HLA 62, 33
- Gastroenteropathy;** Diabetes mellitus; Aldose reductase inhibitor 62, 69

- GDM**; Screening test; Glucose challenge test 62, 47
- Genetic susceptibility**; Type 2 diabetes mellitus; PPAR γ gene 62, 105
- Gestational diabetes mellitus**; Screening; Prevalence; Risk factors 62, 131
- Glucose challenge test**; Screening test; GDM 62, 47
- HLA**; Fulminant type 1 diabetes; Pregnancy; Viral infection; GADab 62, 33
- HOMA-IR**; Nateglinide; Insulin resistance 62, 87
- Hyperglycemia**; Pulse wave velocity; Insulin; Type 2 diabetic patients 62, 17
- Hyperlipidemia**; Leptin receptor (Ob-R); SNPs (single nucleotide polymorphisms); Modifier gene; Pharmacogenetic traits 62, 169
- Impaired fasting glucose**; Diabetes diagnosis; Oral glucose tolerance test; Impaired glucose tolerance; Primary care 62, 123
- Impaired glucose tolerance**; Diabetes diagnosis; Oral glucose tolerance test; Impaired fasting glucose; Primary care 62, 123
- Insulin**; Pulse wave velocity; Hyperglycemia; Type 2 diabetic patients 62, 17
- Insulin action**; Cinnamon extract; Euglycemic clamp; Insulin signaling 62, 139
- Insulin mixtures**; Type 2 diabetes; Oral agents 62, 187
- Insulin resistance**; Nateglinide; HOMA-IR 62, 87
- Insulin signaling**; Cinnamon extract; Euglycemic clamp; Insulin action 62, 139
- Intensive insulin treatment**; Lispro insulin; Type 2 diabetes 62, 79
- Intra-abdominal fat**; Diabetes mellitus; Lipoprotein lipase mass; Remnant-like particle; Leptin 62, 39
- Japanese**; *Pro12Ala PPAR γ 2* polymorphism; Type 2 diabetes; Carotid artery intima-media thickness; Atherosclerosis 62, 55
- Leptin**; Diabetes mellitus; Lipoprotein lipase mass; Intra-abdominal fat; Remnant-like particle 62, 39
- Leptin receptor (Ob-R)**; Hyperlipidemia; SNPs (single nucleotide polymorphisms); Modifier gene; Pharmacogenetic traits 62, 169
- Lipoprotein lipase mass**; Diabetes mellitus; Intra-abdominal fat; Remnant-like particle; Leptin 62, 39
- Lispro insulin**; Type 2 diabetes; Intensive insulin treatment 62, 79
- Microalbuminuria**; Diabetes; Nephropathy; Blood pressure; Diurnal variation 62, 159
- Modifier gene**; Leptin receptor (Ob-R); Hyperlipidemia; SNPs (single nucleotide polymorphisms); Pharmacogenetic traits 62, 169
- Nateglinide**; HOMA-IR; Insulin resistance 62, 87
- Nephropathy**; Diabetes; Blood pressure; Diurnal variation; Microalbuminuria 62, 159
- Obesity**; Ethnicity; Roma; Cardiovascular disease; Type 2 diabetes 62, 95
- Obesity**; Tumour necrosis factor alpha polymorphism; Weight loss 62, 197
- Oral agents**; Type 2 diabetes; Insulin mixtures 62, 187
- Oral glucose tolerance test**; Diabetes diagnosis; Impaired fasting glucose; Impaired glucose tolerance; Primary care 62, 123
- Peroxisome proliferator-activated receptor gamma**; Plasminogen activator inhibitor type 1; Troglitazone; Endothelial cell 62, 1
- Pharmacogenetic traits**; Leptin receptor (Ob-R); Hyperlipidemia; SNPs (single nucleotide polymorphisms); Modifier gene 62, 169
- Plasma glucose**; Type 2 diabetes in adult Nigerians; Body mass index 62, 177
- Plasminogen activator inhibitor type 1**; Peroxisome proliferator-activated receptor gamma; Troglitazone; Endothelial cell 62, 1
- PPAR γ gene**; Type 2 diabetes mellitus; Genetic susceptibility 62, 105
- Preference**; Utility; Quality of life; Diabetes; SF-36 62, 9
- Pregnancy**; Fulminant type 1 diabetes; Viral infection; HLA; GADab 62, 33
- Prevalence**; Gestational diabetes mellitus; Screening; Risk factors 62, 131

- Primary care;** Diabetes diagnosis; Oral glucose tolerance test; Impaired fasting glucose; Impaired glucose tolerance 62, 123
- Pro12Ala PPAR γ 2 polymorphism;** Type 2 diabetes; Carotid artery intima-media thickness; Atherosclerosis; Japanese 62, 55
- Pulse wave velocity;** Insulin; Hyperglycemia; Type 2 diabetic patients 62, 17
- Quality of life;** Utility; Preference; Diabetes; SF-36 62, 9
- Remnant-like particle;** Diabetes mellitus; Lipoprotein lipase mass; Intra-abdominal fat; Leptin 62, 39
- Risk factors;** Gestational diabetes mellitus; Screening; Prevalence 62, 131
- Roma;** Ethnicity; Obesity; Cardiovascular disease; Type 2 diabetes 62, 95
- Screening;** Gestational diabetes mellitus; Prevalence; Risk factors 62, 131
- Screening test;** Glucose challenge test; GDM 62, 47
- SF-36;** Utility; Preference; Quality of life; Diabetes 62, 9
- SNPs (single nucleotide polymorphisms);** Leptin receptor (Ob-R); Hyperlipidemia; Modifier gene; Pharmacogenetic traits 62, 169
- Stroke;** Diabetes mellitus; Thyrotropin 62, 203
- Thyrotropin;** Stroke; Diabetes mellitus 62, 203
- Troglitazone;** Plasminogen activator inhibitor type 1; Peroxisome proliferator-activated receptor gamma; Endothelial cell 62, 1
- Tumour necrosis factor alpha polymorphism;** Obesity; Weight loss 62, 197
- Type 2 diabetes;** Ethnicity; Roma; Obesity; Cardiovascular disease 62, 95
- Type 2 diabetes;** Lispro insulin; Intensive insulin treatment 62, 79
- Type 2 diabetes;** Oral agents; Insulin mixtures 62, 187
- Type 2 diabetes;** Pro12Ala PPAR γ 2 polymorphism; Carotid artery intima-media thickness; Atherosclerosis; Japanese 62, 55
- Type 2 diabetes in adult Nigerians;** Plasma glucose; Body mass index 62, 177
- Type 2 diabetes mellitus;** PPAR γ gene; Genetic susceptibility 62, 105
- Type 2 diabetic patients;** Pulse wave velocity; Insulin; Hyperglycemia 62, 17
- Utility;** Preference; Quality of life; Diabetes; SF-36 62, 9
- Viral infection;** Fulminant type 1 diabetes; Pregnancy; HLA; GADab 62, 33
- Visceral adipose tissue;** Anthropometric parameters; Computed tomography 62, 149
- Weight loss;** Tumour necrosis factor alpha polymorphism; Obesity 62, 197

